English articles
- Sales of a Star Heart Drug Have Halved. Can Novartis’s Next Medicines Take Over in Time?
- From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?
- Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?
- One Less Search for a Vein, a Little More Freedom in Life with Hemophilia
- PharmaEssentia Acquires FormuRx. Could Making Drugs Inside Cells Be Next?
- Weight-Loss Injections: The Goal Is to Lose Weight, Not Hair
- Adding an ADC to Lung Cancer Immunotherapy: More Tumor Responses, but Why Did Phase 3 Fall Short?
- Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?
- Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash
- US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?
- New Hepatitis B Drug Approved in Japan: About One in Five Treated Trial Patients Achieved a “Functional Cure”
- A new US therapy for muscle-wasting disease: bringing four-weekly infusions into everyday care
- Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D
- Why Are Lilly and Novartis Betting on How Medicines Are Delivered?
- Moderna’s Cancer Vaccine Delivers Positive News—Investors Should Also Understand This Example of “Acting Earlier”
- After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt?
- PharmaEssentia Wins a New Indication: How Can a Taiwan-Developed Drug Become a Global Business?
- Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard
- Claude Starts Running Experiments: AI Enters the Physical Lab
- A New Drug Launched. Seven Months Later, the Company Sought Liquidation
- Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here
- GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue?
- Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight
- Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval
- A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million
- DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet
- Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses?
- The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD?
- Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business
- Who Could Be Big Pharma's Next Major Biotech Acquisition?
